John Deans, MD
Ophthalmology · Wilmington, NCNPI 1407210057
Payments from drug & device makers
Across 70 payments — averaging $43.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$890
- Notal Vision, Inc.$546
- Regeneron Healthcare Solutions, Inc.$315
- Bausch & Lomb Americas Inc.$307
- Genentech USA, Inc.$228
- AbbVie$197
- plus $551 from 10 others
What the payments were for
- Speaking & faculty fees$1265%
- Food & beverage$2,48895%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 13 | $890 |
| Notal Vision, Inc. | 11 | $546 |
| Regeneron Healthcare Solutions, Inc. | 8 | $315 |
| Bausch & Lomb Americas Inc. | 4 | $307 |
| Genentech USA, Inc. | 6 | $228 |
| AbbVie | 9 | $197 |
| Astellas Pharma US Inc | 7 | $188 |
| Alcon | 1 | $105 |
| Harrow Eye, LLC | 2 | $56 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $46 |
| Glaukos Corporation | 2 | $43 |
| Alimera Sciences, Inc. | 2 | $38 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| Topcon Healthcare, Inc. | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$124
- VABYSMO$122
- INFUSE$120
- Tecnis Symfony IOL$102
How this compares
$3,035 in reported general payments places this provider in the 65th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 184 | $7,965 |
| Atropine Sulfate | 71 | $2,648 |
| MoxifloxacinMoxifloxacin Hcl | 114 | $2,426 |
| Bromfenac Sodium | 14 | $1,843 |
| Ketorolac Tromethamine | 53 | $1,556 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 67 | $1,236 |
| Brimonidine Tartrate | 30 | $859 |
| ValacyclovirValacyclovir Hcl | 17 | $455 |
| Latanoprost | 36 | $312 |
| Timolol Maleate | 30 | $273 |
| Prednisone | 17 | $92 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Wilmington
- Clark SpringsWilmington$300K
- Leon CharkoudianWilmington$112K
- Robert van der VaartWilmington$50K
- Glenn JaffeDurham$38.5M
- Lejla VajzovicDurham$7.5M
- Andrew AntoszykCharlotte$4M
- Majda HadziahmetovicDurham$2.4M
- Preeya GuptaRaleigh$2M
- Thomas WilliamsHickory$1.8M
- James HarrisHickory$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.